Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2326 - 2350 of 14983 in total
Nimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old. Due to concerns about the risk of hepatotoxicity, nimesulide has...
Approved
Investigational
Withdrawn
Matched Description: … primary dysmenorrhoea in adolescents and adults above 12 years old. ... Nimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and ... Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and
Matched Categories: … Antiinflammatory and Antirheumatic Products ... Topical Products for Joint and Muscular Pain ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Cushing's syndrome (CS) is underpinned by chronic hypercortisolism leading to multisystem morbidity, including effects on the cardiovascular and endocrine systems, metabolic syndrome with accompanying changes in body composition, neuropsychiatric effects, changes in blood pressure and chemistry, and opportunistic infections.[A244078, A244083] Ketoconazole has been used both on- and off-label to treat...
Approved
Investigational
Matched Description: … chemistry, and opportunistic infections. ... chronic hypercortisolism leading to multisystem morbidity, including effects on the cardiovascular and ... with accompanying changes in body composition, neuropsychiatric effects, changes in blood pressure and
Matched Categories: … Sex Hormones and Insulins …
Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and...
Approved
Matched Description: … LABAs including improved convenience and compliance and improved airflow over a 24-hour period. ... novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and ... signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and
Matched Categories: … olodaterol and tiotropium bromide …
Fremanezumab is a humanized monoclonal antibody targeted against human calcitonin gene-related peptide (CGRP) for the prevention of migraine headaches. It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. Along with other recently approved anti-CGRP therapies such as galcanezumab, erenumab, and the oral CGRP antagonist...
Approved
Investigational
Matched Description: … [L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. ... [L11779] Along with other recently approved anti-CGRP therapies such as [galcanezumab], [erenumab], and ... oral CGRP antagonist [ubrogepant], fremanezumab represents an important step forward in the treatment and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis . The use of gold compounds has decreased since the 1980s...
Approved
Withdrawn
Matched Description: … use of gold compounds has decreased since the 1980s owing to numerous side effects, limited efficacy, and ... Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and ... replaced with the use of various current disease modifying anti-rheumatic drugs (DMARDs) like methotrexate and
Matched Categories: … Antiinflammatory and Antirheumatic Products …
Oil extracted from olives . Consists primarily of the glycerides of the fatty acids linoleic, oleic and palmitic. Used as a source of fatty acids in total parenteral nutrition and as an additive in some cosmetic products [FDA Label].
Approved
Matched Description: … Consists primarily of the glycerides of the fatty acids linoleic, oleic and palmitic. ... Used as a source of fatty acids in total parenteral nutrition and as an additive in some cosmetic products …
Matched Categories: … Diet, Food, and Nutrition …
Approved
Experimental
Matched Categories: … Herbs and Natural Products …
Saw palmetto is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Approved
Experimental
Investigational
Matched Categories: … Herbs and Natural Products …
In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.
Approved
Withdrawn
Matched Categories: … Medications that reduce magnesium levels …
Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.
Approved
Withdrawn
Matched Categories: … Medications that reduce magnesium levels …
Approved
Matched Iupac: … lambda2-iron(2+) (2R)-2-amino-3-sulfanylpropanoic acid 2-aminoacetic acid (2R)-2-amino-3-sulfanidylpropanoate …
Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors. Letermovir has recieved both priority and orphan drug status...
Approved
Investigational
Matched Iupac: … -5-(trifluoromethyl)phenyl]-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3,4-dihydroquinazolin-4-yl]acetic acid
Matched Description: … [A31290] Letermovir has recieved both priority and orphan drug status from the FDA. …
In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients.
Approved
Investigational
Withdrawn
Matched Description: … The FDA issued a warning letter regarding this risk to health care professionals and patients. …
Matched Categories: … Alimentary Tract and Metabolism ... Benzamides and benzamide derivatives …
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is available in oral, transdermal, and...
Approved
Vet approved
Matched Description: … Meloxicam is available in oral, transdermal, and intravenous formulations. ... relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and
Matched Categories: … bupivacaine and meloxicam ... Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use....
Approved
Matched Description: … International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and
Matched Categories: … Acid Reducers ... Diazepines, Oxazepines, Thiazepines and Oxepines …
Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist.[A256838,L44918] In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.[L44918,L44948] It received a similar approval in the EU in September 2023. Elacestrant binds to estrogen receptor-alpha (ERα)...
Approved
Investigational
Matched Description: … Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist. ... degrader (SERD) thanks to its ability to block the transcriptional activity of the ER and promote its ... [L49334] Elacestrant binds to estrogen receptor-alpha (ERα) and acts as a selective estrogen receptor …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents …
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular...
Approved
Investigational
Matched Description: … differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression ... 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. ... kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Atopic dermatitis (AD) is an inflammatory skin disorder that causes skin inflammation, skin barrier dysfunction, and chronic pruritus. It is estimated to affect up to 20% of adults and children worldwide, and is frequently associated with other atopic conditions such as asthma or allergic rhinitis. While AD is a heterogenous...
Approved
Investigational
Matched Description: … [A242432] It is estimated to affect up to 20% of adults and children worldwide, and is frequently associated ... was subsequently approved in Canada in October 2021 and the US in December 2021. ... dermatitis (AD) is an inflammatory skin disorder that causes skin inflammation, skin barrier dysfunction, and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Prostate cancer is the most common non-cutaneous malignancy affecting men in North America - despite this, an ongoing challenge in prostate cancer therapy is the difficulty in imaging the extent and location of tumor metastases and recurrences. The images generated by positron emission tomography (PET) are less detailed than those...
Approved
Investigational
Matched Iupac: … 2S)-2-({[(1S)-1-carboxy-5-{[6-(¹⁸F)fluoropyridin-3-yl]formamido}pentyl]carbamoyl}amino)pentanedioic acid
Matched Description: … location of tumor metastases and recurrences. ... and more accurate detection of suspected prostate cancer metastases or recurrences. ... despite this, an ongoing challenge in prostate cancer therapy is the difficulty in imaging the extent and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019.
Approved
Investigational
Matched Description: … -2 and high risk primary and secondary myelofibrosis. ... Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Vonicog alfa is a recombinant von Willebrand factor manufactured by Baxalta. It was FDA approved in December 2015. The gen of von Willebrand factor was first cloned in 1985 by Stuart Orkin and David Ginsburg. By the EMA, vonicog alfa is still under clinical analysis.
Approved
Investigational
Matched Description: … [A32230] The gen of von Willebrand factor was first cloned in 1985 by Stuart Orkin and David Ginsburg …
Zotepine, with the formula (2-chloro-11-(2-dimethyl-amino-ethoxy)-dibenzo thiepin, is a neuroleptic drug. It was designed and synthesized by Fujisawa Pharmaceutical Co Ltd. It has been used as an antipsychotic in Japan, India and some places in Europe like UK and Germany since 1980's. Zotepine was never approved by the FDA. In 1993,...
Approved
Investigational
Withdrawn
Matched Description: … [A31855] It has been used as an antipsychotic in Japan, India and some places in Europe like UK and Germany ... It was designed and synthesized by Fujisawa Pharmaceutical Co Ltd. ... In 1993, it was classified as inactive drug substance (Status I, Type II) and in 1995 the FDA studied …
Nirmatrelvir (PF-07321332) is an orally bioavailable 3C-like protease (3CLPRO) inhibitor that is the subject of clinical trial NCT04756531. 3CLPRO is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2. Without the activity of the SARS-CoV-2 3CLPRO, nonstructural proteins (including proteases) cannot be released to perform their functions, inhibiting viral replication.[A234224,A234229,A234234]...
Approved
Investigational
Matched Description: … [L33354] 3CLPRO is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2. ... in Canada in January 2022 for the treatment of adult patients with mild-moderate COVID-19 [L39544] and ... granted an emergency use authorization to Paxlovid, a co-packaged product containing both nirmatrelvir and
Matched Categories: … nirmatrelvir and ritonavir ... Amino Acids, Peptides, and Proteins …
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , [FDA label]. It was originally...
Approved
Matched Description: … sequences and human constant region sequences [A40017], [FDA label]. ... The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region ... chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and
Matched Categories: … Amino Acids, Peptides, and Proteins ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Omidenepag isopropyl is a topical ocular hypotensive agent used to reduce intraocular pressure (IOP) in patients with glaucoma and ocular hypertension. Omidenepag isopropyl is quickly metabolized to its active metabolite, omidenepag, a molecule with high selectivity and agonistic activity towards the prostaglandin E2 (EP2) receptor.[A253263,A253268] Prostanoid FP receptor agonists (FP...
Approved
Investigational
Matched Description: … topical ocular hypotensive agent used to reduce intraocular pressure (IOP) in patients with glaucoma and ... isopropyl is quickly metabolized to its active metabolite, omidenepag, a molecule with high selectivity and ... [A253253] In 2018, omidenepag isopropyl was approved in Japan for the treatment of glaucoma and ocular …
Displaying drugs 2326 - 2350 of 14983 in total